Overview Request Sample Pages Request Customization Download PDF
You are viewing: Mexico In Vitro Diagnostics Market analysis
Part of: In Vitro Diagnostics Market (Global)

The Mexico In Vitro Diagnostics Market was valued at $853.1 Million in 2025 and projected to reach to $1199.8 Million by 2030, representing a compound annual growth rate of 7.1%. Mexico's in vitro diagnostics market is positioned for sustained growth through 2030, driven by expanding healthcare infrastructure investments and rising demand for diagnostic testing services.

Mexico In Vitro Diagnostics Market Trends and Insights

  • This growth trajectory reflects Mexico's increasing healthcare infrastructure investments and rising demand for diagnostic testing across clinical laboratories and point-of-care settings.
  • Mexico's market expansion is driven by population health awareness, chronic disease prevalence, and modernization of laboratory facilities throughout the country. The Mexican in vitro diagnostics sector benefits from growing adoption of automated diagnostic platforms and molecular testing capabilities.
  • Mexico's healthcare system continues to integrate advanced diagnostic technologies, supporting both public and private laboratory networks.
  • Between 2025 and 2030, Mexico is expected to see accelerated demand for immunoassays, clinical chemistry, and molecular diagnostics as healthcare providers prioritize early disease detection and patient outcomes. Mexico's position within Latin America's broader diagnostic market underscores the country's significance as a regional healthcare hub.
  • The 7.1% compound annual growth rate reflects Mexico's commitment to diagnostic innovation and accessibility, positioning the nation as a key growth market for in vitro diagnostic manufacturers and service providers..

Key Market Statistics

  • CAGR (2025-2030) : 7.1% CAGR
  • Market Size, 2025 : ~USD 853.1
  • Forecast, 2030 : ~USD 1199.8
  • Country : Mexico

Mexico In Vitro Diagnostics Market Overview

Market Valuation Growth :

Mexico's in vitro diagnostics market is valued at USD 853.1 million in 2025, with projections reaching USD 1,199.8 million by 2030, representing a robust 7.1% CAGR over the forecast period.

Healthcare Infrastructure Expansion :

Increasing investments in Mexico's healthcare infrastructure are driving demand for advanced diagnostic testing capabilities across clinical laboratories, hospitals, and point-of-care settings nationwide.

Rising Diagnostic Testing Demand :

Growing population health awareness and chronic disease prevalence in Mexico are fueling increased demand for in vitro diagnostic tests, including immunoassays, molecular diagnostics, and clinical chemistry panels.

Point-of-Care Testing Growth :

Expansion of point-of-care diagnostic solutions in Mexico's rural and underserved regions is accelerating market penetration and improving access to timely diagnostic results across diverse healthcare settings.

Mexico In Vitro Diagnostics Market Dynamics

  • The market benefits from increasing chronic disease prevalence, growing healthcare expenditure, and modernization of clinical laboratory networks across public and private sectors.
  • Government initiatives to strengthen primary healthcare and diagnostic capabilities are expected to support market expansion.
  • Additionally, the adoption of advanced diagnostic technologies and automation in Mexican laboratories will enhance testing efficiency and accessibility, particularly in underserved regions..

Related Ecosystem

In Vitro Diagnostics

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Dna Microarrays
  • Assay Kits
  • Microarrays
Top Companies
  • ROCHE HOLDINGS AG
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Abbott Laboratories
  • Biomerieux s.a.

    Medical Devices

    Top Technologies
    • Polymerase Chain Reaction (PCR)
    • Magnetic Resonance Imaging (MRI)
    • Disposable Autoinjectors
    • Pulse Oximeters
    • Blood Pressure Monitors
    Top Companies
    • Medtronic plc
    • Stryker Corporation
    • Abbott Laboratories
    • Becton, Dickinson and Company
    • JOHNSON & JOHNSON

      Key Takeaways

      • Mexico's in vitro diagnostics market will grow from USD 853.1 million (2025) to USD 1,199.8 million (2030) at a 7.1% CAGR.
      • Mexico's healthcare modernization and chronic disease management drive demand for advanced diagnostic testing solutions.
      • Mexico's laboratory infrastructure expansion supports adoption of automated and molecular diagnostic platforms.
      • Mexico represents a strategic growth opportunity for diagnostic manufacturers within the Latin American region.

      Mexico In Vitro Diagnostics Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment MOLECULAR DIAGNOSTICS (Technology)
      Forecast Period 2025–2030
      Growth Rate CAGR of 7.6% from 2025 to 2030
      Largest Segment REAGENTS & KITS (Product & Service)
      Market Size Base Year 109.29 (2025)
      Revenue Forecast 157.63 (2030)
      Segments Covered Product & Service, Technology, Type, Specimen, Test Type, Application, End User

      Mexico In Vitro Diagnostics Market Report Segmentation

      7 segment dimensions are covered across the global market.

      By Product & Service

      • Data Management Software & Services
      • Data Management Software And Services
      • Instruments
      • Reagents & Kits

      By Technology

      • Blood Gas Analyzers
      • Chromatography & Mass Spectrometry
      • Clinical Chemistry
      • Coagulation & Hemostasis
      • Glucose Monitoring
      • Hematology
      • Immunoassays
      • Microbiology
      • Molecular Diagnostics
      • Urinalysis

      By Type

      • Basic Metabolic Panels
      • Chemiluminescence Immunoassays
      • Dna Microarrays
      • Dna Sequencing & Next-Generation Sequencing (Ngs)
      • Electrolyte Panels
      • Enzyme-Linked Immunosorbent Assays (Elisa)
      • Enzyme-Linked Immunospot Assays (Elispot)
      • Immunofluorescence Assays
      • In Situ Hybridization (Ish)
      • Isothermal Nucleic Acid Amplification Technology (Inaat)
      • Large Reference Laboratories
      • Lipid Profiles
      • Liver Panels
      • Other Immunoassay Technologies
      • Other Molecular Diagnostic Technologies
      • Polymerase Chain Reaction (Pcr)
      • Rapid Tests
      • Renal Profiles
      • Small & Medium-Sized Laboratories
      • Specialty Chemical Tests
      • Thyroid Function Profiles
      • Western Blotting

      By Specimen

      • Blood, Serum, And Plasma Specimens
      • Other Specimens
      • Saliva Specimens
      • Urine Specimens

      By Test Type

      • Laboratory Test
      • Laboratory Tests
      • Point-Of-Care Tests

      By Application

      • Allergy Diagnostics
      • Autoimmune Diseases
      • Blood Group Typing
      • Blood Screening
      • Bone & Mineral Disorders
      • Cardiology
      • Coagulation Testing
      • Drug Monitoring & Testing
      • Endocrinology
      • Genetic Testing
      • Infectious Diseases
      • Oncology
      • Other Applications

      By End User

      • Academic Institutes
      • Blood Banks
      • Clinical Laboratories
      • Home Care Settings
      • Hospitals & Clinics
      • Other End Users
      • Pharmaceutical & Biotechnology Companies

      Target Audience

      • Diagnostic Equipment Manufacturers : IVD equipment manufacturers need Mexico-specific market data to assess market potential, identify distribution channels, and develop localized product strategies for clinical laboratories and healthcare facilities.
      • Healthcare Investors & Private Equity : Investment firms require detailed Mexico market analysis to evaluate acquisition targets, assess growth potential in the diagnostic sector, and make informed capital allocation decisions in the region.
      • Laboratory Service Providers : Clinical laboratory operators and diagnostic service companies need market insights to expand operations, optimize service offerings, and capitalize on growing demand for diagnostic testing across Mexico.
      • Healthcare Consultants & Advisors : Management consultants and healthcare advisors require Mexico-specific IVD market data to support client strategy development, market entry planning, and competitive positioning recommendations.
      • Government & Healthcare Policy Makers : Mexican healthcare authorities and policymakers need market intelligence to inform healthcare infrastructure planning, diagnostic capability development, and regulatory framework decisions for the IVD sector.

      Key Companies in the Mexico In Vitro Diagnostics Market

      CompanyHQOwnershipStrongest segments
      CEPHEID INC.United StatesPrivate CompanyKits / Assays (Xpert test cartridges),Instruments (GeneXpert, SmartCycler),Services & Other (service contracts, collaborations),
      AT&SAustriaPublic CompanyKits (including cartridges and consumables manufacturing systems),Instruments (analyzers and device manufacturing systems),Software & digital factory solutions for IVD plants,
      IMMUCOR, INC.United StatesPrivate CompanyTransfusion serology reagents (manual and Capture),Automated serology instruments (NEO, Echo, Capture Workstation),Transplant & molecular assays (HEA/HPA typing, Array Imaging System, BASIS),
      UNILABSSwitzerlandPrivate CompanyKits (consumed in internal labs and managed services),Instruments (installed base within owned and in-house labs),IVD Service Revenue (testing, reporting, and clinical trial support),
      EIKEN CHEMICAL CO., LTD.JapanPublic CompanyKits & Reagents (microbiology, FIT, immunology, serology, urinalysis, clinical chemistry),Instruments & Automated Analyzers,
      DANAHERUnited StatesPublic CompanyKits & Consumables,Instruments,Software & Services,
      ABBOTTUnited StatesPublic CompanyKits & Reagents,Instruments (Core Lab & Hematology),Glucose Monitoring Systems,
      SIEMENS HEALTHINEERS AGGermanyPublic CompanyKits & Reagents,Instruments (Core Lab Analyzers and Hematology Systems),Point-of-Care and Glucose Monitoring,
      THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyKits & Reagents,Instruments & Analyzers,Services & Others (IVD-related),
      ILLUMINA, INC.United StatesPublic CompanySequencing instruments,Sequencing consumables (reagents, flow cells),Library preparation and targeted/whole-genome kits,
      HOLOGIC, INC.United StatesPrivate CompanyMolecular infectious disease and women’s health assays (Aptima portfolio),Cytology and cervical cancer screening (ThinPrep and related solutions),Other diagnostic assays and instruments (including viral load, SARS-CoV-2, and fetal fibronectin),
      BIO-RAD LABORATORIES, INC.United StatesPublic CompanyKits & Reagents (including QC),Instruments & Systems,Informatics & Software / Services,
      BIOMÉRIEUXFrancePublic CompanyKits & Reagents (including panels, media, CLIA, PCR, AST strips),Instruments & Systems (BACT/ALERT, BIOFIRE platforms, VITEK, VIDAS, CHEMUNEX, TEMPO),Software, Services & Lab Consultancy,
      SYSMEX CORPORATIONJapanPublic CompanyHematology instruments,Hematology reagents and consumables,Coagulation and hemostasis,
      REVVITYUnited StatesPublic CompanyKits & Reagents,Instruments & Analyzers,Software, Subscriptions & Services,
      BECTON, DICKINSON AND COMPANYUnited StatesPublic CompanyKits & Reagents (including microbiology media, TB, infectious disease assays),Instruments & Lab Automation (microbiology, blood culture, identification/susceptibility, flow cytometry),Specimen & Blood Collection Systems,
      AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyInstruments (analyzers, LC/MS, pathology platforms),Kits, reagents, and consumables,Services, software, and informatics (CrossLab, OpenLab),
      QIAGENNetherlandsPublic CompanyKits & Consumables (sample technologies, immune response, oncology, infectious disease assays),Instruments (nucleic acid purification, PCR, digital PCR, integrated sample-to-insight systems),Bioinformatics & SaaS (NGS analysis, interpretation, forensic genealogy services),
      DIASORIN S.P.A.ItalyPublic CompanyImmunoassay Kits (LIAISON menu across infectious disease, endocrinology, oncology),Immunoassay Instruments (LIAISON XL, LIAISON XS),Molecular Diagnostics Kits (Simplexa, LIAISON PLEX assays, xMAP-based IVD),

      CEPHEID INC.

      Cepheid Inc. is a private U.S. company founded in 1996 with 1,700 employees. The company develops molecular diagnostics and point-of-care testing systems.

      AT&S

      AT&S is a publicly traded Austrian company founded in 1978 with 7,000 employees. The company manufactures printed circuit boards and electronics components.

      IMMUCOR, INC.

      Immucor, Inc. is a private U.S. company established in 1982 with 1,125 employees. The company develops immunohematology and transfusion diagnostics products.

      UNILABS

      Unilabs is a private Swiss company established in 1987 with 1,897 employees. The company provides clinical laboratory and diagnostic testing services.

      EIKEN CHEMICAL CO., LTD.

      Eiken Chemical Co., Ltd. is a publicly traded Japanese company founded in 1939 with 696 employees. The company manufactures diagnostic reagents and chemical products.

      DANAHER

      Danaher is a publicly traded U.S. company founded in 1969 with 59,000 employees. The company operates a diversified portfolio of businesses in diagnostics, life sciences, and environmental solutions.

      ABBOTT

      Abbott is a publicly traded U.S. company founded in 1888 with 115,000 employees. The company develops and manufactures pharmaceuticals, diagnostics, medical devices, and nutritional products.

      SIEMENS HEALTHINEERS AG

      Siemens Healthineers AG is a publicly traded German company founded in 1896 with 72,369 employees. The company provides medical imaging, laboratory diagnostics, and healthcare IT solutions.

      THERMO FISHER SCIENTIFIC INC.

      Thermo Fisher Scientific Inc. is a publicly traded U.S. company founded in 1956 with 125,000 employees. The company supplies life sciences, analytical instruments, reagents, and laboratory services globally.

      ILLUMINA, INC.

      Illumina, Inc. is a publicly traded U.S. company founded in 1998 with 8,625 employees. The company develops and manufactures DNA sequencing and genetic analysis systems.

      HOLOGIC, INC.

      Hologic, Inc. is a private U.S. company founded in 1985 with 7,070 employees. The company develops medical devices and diagnostics for women's health and oncology.

      BIO-RAD LABORATORIES, INC.

      Bio-Rad Laboratories, Inc. is a publicly traded U.S. company founded in 1952 with 7,450 employees. The company manufactures clinical diagnostics, life science research products, and quality control systems.

      BIOMÉRIEUX

      bioMérieux is a publicly traded French company founded in 1963 with 14,894 employees. The company develops in vitro diagnostics and microbiology testing solutions.

      SYSMEX CORPORATION

      Sysmex Corporation is a publicly traded Japanese company founded in 1968 with 10,861 employees. The company manufactures hematology, hemostasis, and clinical chemistry diagnostic systems.

      REVVITY

      Revvity is a publicly traded U.S. company founded in 1937 with 11,000 employees. The company provides analytical instruments, software, and services for life sciences and diagnostics.

      BECTON, DICKINSON AND COMPANY

      Becton, Dickinson and Company is a publicly traded U.S. company founded in 1897 with 72,000 employees. The company manufactures medical devices, diagnostics, and laboratory equipment.

      AGILENT TECHNOLOGIES, INC.

      Agilent Technologies, Inc. is a publicly traded U.S. company founded in 1999 with 18,000 employees. The company develops analytical instruments, software, and services for life sciences and diagnostics.

      QIAGEN

      QIAGEN is a publicly traded Dutch company founded in 1984 with 5,500 employees. The company develops molecular diagnostics, sample preparation, and life sciences research products.

      DIASORIN S.P.A.

      DiaSorin S.p.A. is a publicly traded Italian company founded in 1968 with 3,242 employees. The company manufactures immunodiagnostic and molecular diagnostic systems.

      Reasons to Buy this Report

      • Market Size & Growth Projections : Access precise valuation data for Mexico's IVD market (USD 853.1M in 2025) with detailed 5-year forecasts to 2030, enabling accurate business planning and investment decisions specific to the Mexican market.
      • Competitive Landscape Analysis : Understand Mexico-specific market dynamics, key players, and competitive positioning within the country's in vitro diagnostics sector to identify partnership and expansion opportunities.
      • Healthcare Infrastructure Insights : Gain detailed intelligence on Mexico's healthcare infrastructure investments, laboratory modernization trends, and regulatory environment affecting diagnostic testing adoption and market growth.
      • Segment & Application Breakdown : Analyze Mexico's diagnostic testing segments including clinical chemistry, immunoassays, molecular diagnostics, and point-of-care testing to identify high-growth opportunities and market gaps.
      • Strategic Market Entry Planning : Leverage Mexico-focused market research to develop targeted go-to-market strategies, distribution partnerships, and product positioning aligned with local healthcare needs and regulatory requirements.

      Frequently asked questions

      What is the current size of Mexico's in vitro diagnostics market?

      Mexico's in vitro diagnostics market is valued at USD 853.1 million in 2025, with expectations to reach USD 1,199.8 million by 2030.

      What is the projected growth rate for Mexico's in vitro diagnostics market?

      Mexico's in vitro diagnostics market is projected to grow at a compound annual growth rate (CAGR) of 7.1% from 2025 to 2030.

      What factors are driving growth in Mexico's diagnostic market?

      Mexico's diagnostic market growth is driven by healthcare infrastructure modernization, rising chronic disease prevalence, increased health awareness, and adoption of advanced laboratory technologies.

      Which diagnostic segments are growing fastest in Mexico?

      Immunoassays, clinical chemistry, and molecular diagnostics are experiencing accelerated adoption in Mexico as healthcare providers prioritize early disease detection.

      How does Mexico's market compare to other Latin American countries?

      Mexico is a key regional healthcare hub within Latin America, with significant diagnostic infrastructure and market potential that positions it as a strategic growth market for diagnostic manufacturers.

      RESEARCH METHODOLOGY

      This study involved the extensive use of primary and secondary sources. A comprehensive study was conducted using secondary research methods to gather data about the market, its parent market, and its peer markets. The next stage involved conducting primary research to confirm these conclusions and assumptions and sizing with industry experts throughout the value chain. A combination of top-down and bottom-up methods was used to assess the overall market size. The market sizes of segments and subsegments were then estimated using data triangulation techniques and market breakdown.

      Secondary Research

      The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, investor presentations, SEC filings of companies and publications from government sources [such as National Institutes of Health (NIH), US FDA, US Census Bureau, World Health Organization (WHO), International Trade Administration (ITA), American Association for Clinical Chemistry (AACC), American Diabetes Association (ADA), Association for Molecular Pathology (AMP) and Centers for Medicare and Medicaid Services (CMS) were referred to identify and collect information for the global in vitro diagnostics market study. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

      Primary Research

      In the primary research process, various sources from the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the in vitro diagnostics market. The primary sources from the demand side include hospitals & clinics, clinical laboratories, blood banks, pharmaceutical and biotechnology companies, and academic institutes. Primary research was conducted to validate the market segmentation, identify key players, and gather insights on key industry trends & key market dynamics.

      A breakdown of the primary respondents is provided below:

      In Vitro Diagnostics Market

      Note 1: C-level primaries include CEOs, CFOs, COOs, and VPs.

      Note 2: Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

      Note 3: Tiers are defined based on a company’s total revenue. As of 2023, Tier 1= >USD 10 billion, Tier 2 = USD 1 billion to USD 10 billion, and Tier 3 = < USD 1 billion.

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      For the global market value, annual revenues were calculated based on the revenue mapping of major product manufacturers and OEMs active in the global in vitro diagnostics market. All the major product manufacturers were identified at the global and/or country/regional level. Revenue mapping for the respective business segments/subsegments was done for the major players. The global in vitro diagnostics market was split into various segments and sub-segments based on:

      • List of major players operating in the products market at the regional and/or country level.
      • Product mapping of various in vitro diagnostics manufacturers at the regional and/or country level.
      • Mapping of annual revenue generated by listed major players from in vitro diagnostics (or the nearest reported business unit/product category).
      • Extrapolation of the revenue mapping of the listed major players to derive the global market value of the respective segments/subsegments.
      • Summation of the market value of all segments/subsegments to arrive at the global in vitro diagnostics market.

      The above-mentioned data was consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report.

      Market Size Estimation (Bottom-up Approach & Top-down Approach)

      In Vitro Diagnostics Market

      Data Triangulation

      After arriving at the overall size of the global in vitro diagnostics market through the above-mentioned methodology, this market was split into several segments and subsegments. Where applicable, the data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact market value data for the key segments and subsegments. Examining several macro variables and regional trends from demand- and supply-side players helped triangulate the extrapolated market data.

      Market Definition

      IVD tests are non-invasive tests performed to diagnose, monitor, screen, and assess diseases and health conditions. The term "in vitro," which refers to "in glass," signifies that test tubes or petri dishes are typically used in these tests. These tests are performed artificially on biological samples (blood, urine, and tissues). IVD has a broad scope ranging from sophisticated technologies performed in clinical laboratories to simple and easy-to-use rapid testing kits.

      IVD is used to assess a person's health. This technique is used in precision medicine to determine the suitable course of treatment for particular patients and diagnose and prevent diseases and other medical disorders.

      Stakeholders

      • Transfection products manufacturing companies
      • Pharmaceutical & Biopharmaceutical Companies
      • Chemical Companies
      • Biopharmaceutical Companies
      • Contract Research Organizations (CROs)
      • Contract Development and Manufacturing Organizations (CDMOs)
      • Research Institutes and Universities 
      • Venture Capitalists & Investors
      • Government Associations

      Report Objectives

      • To define, describe, and forecast the in vitro diagnostics (IVD) market based on product & service, technology, specimen, site of testing, application, end user, and region.
      • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and industry-specific challenges).
      • To assess the in vitro diagnostics market with respect to Porter’s Five Forces, regulatory landscape, the value chain, the supply chain, ecosystem analysis, patent protection, pricing assessment, key stakeholders, and buying criteria.
      • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market.
      • To analyze the opportunities in the IVD market for stakeholders and provide details of the competitive landscape for market leaders.
      • To forecast the size of the IVD market in six primary regions (along with countries)—North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa, and the GCC Countries.
      • To profile the key players operating in the IVD market and comprehensively analyze their core competencies and market shares.
      • To track and analyze competitive developments such as partnerships, agreements, collaborations, acquisitions, expansions, product/technology developments, and product approvals.
      • To benchmark players within the IVD market using the Company Evaluation Quadrant framework, which analyzes market players on various parameters within categories of business strategies, market share, and product offerings.

       

      Get the Full In Vitro Diagnostics Market Report

      Full forecast, segment splits, and company analysis for all In Vitro Diagnostics Market.

      Download Sample Pages Buy Report

      METHODOLOGY

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      Cite this Research
      DMCA.com Protection Status